KDR and renal cell carcinoma: The ASSURE (adjuvant sunitinib or sorafenib for unfavorable renal cell carcinoma) phase 3 trial led by the ECOG was the first to use VEGFR TKIs in the adjuvant RCC setting after RN [18].